Lupus & antiphospholipid syndrome
Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab
Authors' conclusion
In this small case series, we found that belimumab was well tolerated in pregnant SLE patients. There were no safety signals for the mothers or their babies.
Study context
- Population
- Pregnant systemic lupus erythematosus (SLE) patients exposed to belimumab
- Participants
- 4 patients
- Exposure
- Belimumab continued until late pregnancy vs discontinued in early pregnancy
- Continued belimumabn = 2
- Discontinued belimumabn = 2reference
- Outcome
- Tolerability and neonatal outcomes
Methodological detailswith summary of 6 previously published case reports and case series
- With summary of 6 previously published case reports and case series
Main finding
As reported in the abstract
- All the four women tolerated belimumab
- Newborns have all developed normally and continue without complications
Observational data: associations, not effects.
Safety
Neonatal complications · 1 year of follow-up
- Newborns all developed normally, without complications
Original publication
Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →